Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects

The histone deacetylase (HDAC) inhibitors have been demonstrated as an emerging class of anticancer drugs. HDACs are involved in regulation of gene expression and in chromatin remodeling, thus indicating valid targets for different types of cancer therapeutics. The pan-deacetylase inhibitor panobino...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Avineesh, Patel, Vijay K., Jain, Deepak K., Patel, Preeti, Rajak, Harish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315073/
https://www.ncbi.nlm.nih.gov/pubmed/28261641
http://dx.doi.org/10.1007/s40487-016-0023-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315073/
https://www.ncbi.nlm.nih.gov/pubmed/28261641
http://dx.doi.org/10.1007/s40487-016-0023-1

Ejemplares similares